Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments to CMS on Proposed NCD for Coverage of NGS for Medicare Beneficiaries with Advanced Cancer (CAG-00450N)
-
Group Sign-on Letter to Congress (House) Opposing President’s Proposal to Eliminate Funding for HRSA’s Heritable Disorders Program
-
Group Sign-on Letter to Congress (Senate) Opposing President’s Proposal to Eliminate Funding for HRSA’s Heritable Disorders Program
-
Group Sign-on Letter to Congress Supporting the Local Coverage Determination Clarification Act of 2017
-
ACMG/AMP/IDSA Joint Congressional Briefing on LDTs
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (slides)
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (recording)
-
ACMG Response to FDA’s Proposed Regulatory Framework for LDTs
-
ACMG One-Pager on FDA’s Proposed Regulatory Framework for LDTs
-
Group Sign-on Letter to Congress Urging Modernization of the Clinical Laboratory Improvement Amendments (CLIA)